Research and Collaborations

The aim of this research is to assess the effectiveness of drug treatments for substance use disorders—including opioids, alcohol, tobacco, cannabis, and stimulants—by corroborating their therapeutic potential through retrospective cohort studies using EHRs and further collaborating with biomedical researchers to conduct in vitro and in vivo biomedical testing to understand their mechanisms of action.

The aim of this research is to develop a drug repurposing strategy for substance use disorder. The strategy combines AI-based drug prediction, expert panel review, clinical corroboration through EHR-based testing, and data-driven mechanisms of action analysis. Our drug repurposing strategy is highly generalizable and dynamic and can be used for drug discovery for other substance use disorders.

The aim of this research is to develop an integrated, multi-dimensional, knowledge-driven systems approach to identify and explore the complex interactions between microbial metabolites, microglia, and Alzheimer's disease (AD) pathology. Furthermore, we collaborate with wet lab teams to experimentally validate these associations in mouse models of AD. Our research also extends to Parkinson’s disease, amyotrophic lateral sclerosis, pain, and other neurological disorders.

This project aims to explore the impact of antihistamine treatment on white blood cell counts in allergy patients using a nationwide EHR database, employing advanced statistical techniques to assess the risk of elevated WBC compared to alternative anti-allergy medications.